Funded by the Centers for
Disease Control and Prevention
- Partial Responder: A patient who has a decrease in the HCV RNA level of at least 2 log10 IU/ml from baseline by week 12 of treatment, but the HCV RNA remains detectable at week 24 of treatment. The partial responders are a subset of nonresponders.
- Precore mutation: These mutations occur in the precore region of the hepatitis B DNA and can emerge spontaneously or under drug pressure. The precore DNA mutations result in a mRNA stop codon that effectively prevents the production of HBeAg. Patients who have these mutations can have active liver disease with high HBV DNA levels after HBeAg seroconversion.
- Primary non-response: A decrease in serum HBV DNA by less than 2 log10 IU/mL after at least 24 weeks of antiviral therapy.
- Protease inhibitors, HCV NS3/4A: Among the first approved class of direct-acting antiviral agents is the HCV NS3/4A protease inhibitor. These drugs inhibit the NS3/4A serine protease, which is responsible for cleaving the HCV polyprotein precursor, an essential step in the HCV viral lifecycle.